List of Excipients in Branded Drug RADICAVA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Shionogi Inc	RADICAVA	edaravone	70510-2171	CYSTEINE HYDROCHLORIDE
Shionogi Inc	RADICAVA	edaravone	70510-2171	PHOSPHORIC ACID
Shionogi Inc	RADICAVA	edaravone	70510-2171	SODIUM BISULFITE
Shionogi Inc	RADICAVA	edaravone	70510-2171	SODIUM CHLORIDE
Shionogi Inc	RADICAVA	edaravone	70510-2171	SODIUM HYDROXIDE
Shionogi Inc	RADICAVA	edaravone	70510-2171	WATER

RADICAVA Excipient Strategy and Commercial Opportunities in Edaravone Formulations

Last updated: August 2, 2026

Radicava is an edaravone product with two distinct formulation platforms: an intravenous solution and Radicava ORS, an oral suspension. The excipient opportunity is concentrated in oral-liquid competition, taste masking, dose-measurement systems, sulfite-free parenteral alternatives, and manufacturing technologies that improve stability without weakening the product’s regulatory profile.

What formulations does Radicava use?

Radicava is marketed in the United States by Mitsubishi Tanabe Pharma America for amyotrophic lateral sclerosis, or ALS. The FDA approved the intravenous formulation in 2017 and Radicava ORS in 2022.[1,2]

Product	Dosage form	Strength	Administration	Primary excipient issue
Radicava	Intravenous solution	30 mg/100 mL	60-minute infusion	Oxidation control, sulfite sensitivity, container compatibility
Radicava ORS	Oral suspension	105 mg/5 mL	Oral dosing, fasting requirements	Taste, suspension uniformity, dose accuracy, physical stability

The oral dose of 105 mg/5 mL is equivalent to the 105 mg dose used in the approved intravenous dosing regimen. The oral product is supplied as a ready-to-use suspension rather than a tablet or capsule, which creates a larger excipient and device opportunity than a conventional solid oral generic.

What excipients are used in Radicava?

Intravenous formulation

The approved intravenous product contains edaravone with sodium bisulfite and other pH-control and tonicity components. The formulation is packaged in a 100 mL container and is administered by infusion.[1]

The strategic role of the principal excipient classes is as follows:

Excipient class	Likely function in Radicava IV	Commercial relevance
Sodium bisulfite	Antioxidant and oxygen-scavenging support	Creates sulfite-sensitivity and labeling considerations
Amino-acid or sulfur-containing stabilizer system	Oxidation control	May support edaravone chemical stability
Sodium chloride	Tonicity adjustment	Standard parenteral excipient with limited differentiation
Phosphate or other acid-base components	pH control	Controls degradation and container compatibility
Sodium hydroxide or acid	Final pH adjustment	Manufacturing-control requirement
Water for injection	Vehicle	Sterile manufacturing and endotoxin control

The IV formulation has a narrow commercial path for excipient substitution. Any change to the antioxidant system, pH, oxygen exposure, container, or sterilization process can affect edaravone degradation, particulate formation, extractables, leachables, and infusion compatibility.

Sodium bisulfite is the most commercially relevant excipient issue. Sulfites can cause hypersensitivity reactions, particularly in susceptible patients. A sulfite-free edaravone formulation could create differentiation, but it would require evidence that the replacement system maintains stability through manufacturing, storage, and administration.

Radicava ORS formulation

The FDA label identifies the following inactive ingredients for Radicava ORS: citric acid anhydrous, disodium phosphate anhydrous, polysorbate 80, sodium hydroxide, sucralose, and water for injection.[2]

Excipient	Function in oral suspension	Strategic assessment
Citric acid anhydrous	Acidification and flavor support	Helps define pH and perceived sourness
Disodium phosphate anhydrous	Buffer capacity	Balances citric acid and controls pH drift
Polysorbate 80	Wetting and dispersion support	Relevant to suspension uniformity and oxidation risk
Sodium hydroxide	pH adjustment	Controls final formulation conditions
Sucralose	Sweetener and taste masking	Important because edaravone has an unfavorable taste profile
Water for injection	Vehicle	Supports controlled microbiological quality

The oral product’s excipient strategy is more commercially defensible than a simple liquid generic because the formulation must manage several variables simultaneously: edaravone chemical stability, sedimentation, redispersibility, taste, dose uniformity, microbial quality, container closure, and patient use under fasting conditions.

What excipient strategies are available for Radicava competitors?

Can a competitor develop a better oral suspension?

Yes. The highest-value opportunity is a differentiated oral edaravone liquid that maintains the same active ingredient and dose while improving one or more of the following:

1. Taste and mouthfeel.
2. Suspension redispersibility.
3. Dose accuracy after storage.
4. In-use stability.
5. Packaging and portability.
6. Ease of administration for patients with dysphagia.
7. Reduced reliance on polysorbate 80.
8. Reduced microbial-control burden.
9. Better compatibility with oral syringes and feeding tubes.

Radicava ORS uses a sweetened aqueous suspension. That platform can be challenged with alternative wetting agents, structured vehicles, suspending polymers, flavor systems, or solid-to-liquid reconstitution systems. Each approach has regulatory consequences.

What replacement excipients could improve the oral product?

Potential development categories include:

Development objective	Candidate excipient direction	Main technical risk
Improve suspension stability	Cellulose derivatives, xanthan gum, carbomers, or other rheology modifiers	Excessive viscosity and inaccurate syringe dosing
Improve wetting	Poloxamers, lecithin derivatives, or alternative surfactants	Chemical interaction, foaming, and oxidation
Improve taste	High-intensity sweetener blends, flavor systems, taste-masking polymers	pH-dependent flavor changes and patient acceptability
Reduce oxidation risk	Chelators, oxygen-control packaging, alternative antioxidants	New degradation pathways and toxicological review
Improve convenience	Powder for reconstitution or unit-dose sachets	Reconstitution errors and new stability studies
Improve adherence	Smaller-volume concentrate or premeasured doses	Higher concentration can worsen taste and precipitation
Support tube administration	Lower-viscosity suspension with controlled particle size	Settling, clogging, and dose loss in tubing

A competitor should avoid treating excipient substitution as a simple formulation exercise. For an oral suspension, the critical quality attributes include assay, degradation products, particle-size distribution, sedimentation rate, redispersibility, pH, viscosity, microbial limits, preservative effectiveness if applicable, and delivered dose through the supplied device.

What regulatory pathway applies to a generic Radicava product?

A conventional edaravone generic would generally be evaluated under the abbreviated new drug application pathway if the proposed product can meet applicable sameness, bioequivalence, quality, and labeling requirements. A materially different dosage form, route, formulation, or delivery system may require a 505(b)(2) application instead of a standard ANDA.

Product concept	Likely regulatory route	Commercial implication
Same IV solution composition and strength	ANDA, subject to FDA requirements	Lowest formulation differentiation
Same oral suspension strength with different inactive ingredients	Potential ANDA	Excipient changes must not alter performance or bioequivalence
Oral concentrate, reconstitution product, or modified device	Potential 505(b)(2)	More development cost, but greater lifecycle differentiation
Tablet or capsule	Potential 505(b)(2) or new application	Dosing and bioavailability may not be directly interchangeable
Sulfite-free IV formulation	Potential 505(b)(2) or separate product strategy	Opportunity for safety differentiation, but high stability burden
Feeding-tube optimized product	ANDA or 505(b)(2), depending on formulation and labeling	Potential niche in advanced ALS care

For an oral suspension, the device is part of the product’s commercial value. A calibrated oral syringe, bottle adapter, tamper-evident closure, and instructions for resuspension can affect dose delivery and patient adherence. A different device may trigger human-factors and compatibility work even when the active ingredient is unchanged.

When does Radicava lose exclusivity?

The key statutory exclusivity dates are tied to the separate FDA approvals.

Milestone	Date or period
Radicava IV FDA approval	May 5, 2017
Seven-year orphan-drug exclusivity for the original ALS approval	Generally runs through May 2024
Radicava ORS FDA approval	May 12, 2022
Potential three-year new-application exclusivity for clinical investigation supporting the oral formulation	Generally runs through May 2025
Patent expiry	Depends on the specific U.S. patent and any patent-term adjustment or extension

Orphan-drug exclusivity prevents FDA approval of the same drug for the same disease or condition during the exclusivity period, subject to statutory exceptions. It does not prevent all forms of competition, and it does not replace patent protection.

The active ingredient, edaravone, has been commercially available in Japan for many years. The principal U.S. opportunity therefore centers on formulation, dosage form, manufacturing, and regulatory strategy rather than a new-molecule patent position.

What patents protect Radicava formulations?

The relevant U.S. patent analysis should separate four categories:

1. Edaravone composition-of-matter patents.
2. Oral suspension formulation patents.
3. Manufacturing and stability patents.
4. Method-of-use patents covering ALS treatment or dosing regimens.

The original edaravone molecule is unlikely to provide a long-duration U.S. composition-of-matter barrier because the drug predates U.S. approval by many years. The commercially relevant estate is more likely to involve later-filed formulation and dosage-form claims.

A competitor should review:

• FDA Orange Book listings for Radicava and Radicava ORS.
• USPTO patent-family records.
• Patent-term adjustment and terminal-disclaimer data.
• Any listed patents covering the oral suspension, administration method, or formulation.
• Paragraph IV certifications and associated litigation.
• Patent assignments involving Mitsubishi Tanabe Pharma, MTPC, and affiliated entities.

No reliable commercial conclusion should be based on the existence of a formulation patent alone. The practical strength of a patent depends on claim scope, expiry, prosecution history, written-description support, enablement, obviousness risk, and whether a non-infringing alternative formulation can be developed.

What is the Orange Book and Paragraph IV risk for Radicava?

An ANDA applicant must address listed patents through a Paragraph I, II, III, or IV certification, or a section VIII statement where applicable. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed.

The main competitive scenarios are:

Scenario	Likely timing	Business effect
No listed patent blocks the proposed product	After applicable exclusivity	Earlier ANDA launch opportunity
Paragraph III certification	After patent expiry	Predictable but delayed entry
Paragraph IV certification	Before patent expiry	Litigation risk and possible 180-day first-filer benefit
Formulation redesign avoiding listed claims	Before expiry	May reduce litigation exposure
505(b)(2) challenge to a differentiated product	Case-specific	Higher development cost with broader product latitude

The most important diligence question is whether an oral-suspension patent claims the specific combination of edaravone, buffer, surfactant, sweetener, pH range, particle-size profile, or storage conditions. Broad functional claims may create more risk than a narrow list of excipients, but prosecution history can substantially narrow enforceability.

Which companies are positioned to challenge Radicava?

The likely challenger pool includes:

• Large generic manufacturers with oral-liquid manufacturing capacity.
• Specialty pharmaceutical companies focused on neurology.
• Contract development and manufacturing organizations with suspension expertise.
• Excipient suppliers seeking platform access through formulation partnerships.
• Companies developing ALS products that can use edaravone as a combination or adjunct therapy.

The strongest potential entrants are not necessarily the largest tablet manufacturers. A commercially credible challenger needs sterile parenteral capability for IV competition or validated oral-suspension manufacturing, device assembly, and stability infrastructure for Radicava ORS.

What licensing opportunities exist in Radicava excipients?

Licensing value is highest in technologies that solve a defined product problem and can be protected through composition, process, device, or use claims.

High-value licensing targets

• Taste-masking systems compatible with edaravone.
• Sulfite-free antioxidant platforms for parenteral edaravone.
• Low-viscosity suspending systems with improved redispersibility.
• Oxygen-control packaging for oxidation-sensitive drugs.
• Oral syringe and bottle-adapter systems that improve delivered-dose accuracy.
• Feeding-tube compatible suspension technologies.
• Unit-dose packaging that reduces dosing errors.
• Ready-to-reconstitute dry suspensions with long shelf life.

An excipient company should avoid licensing a generic sweetener or buffer package without proprietary performance data. The stronger commercial proposition is a complete platform supported by stability, dose-delivery, sensory, and manufacturing evidence.

How strong is the commercial opportunity?

The market opportunity is defined by treatment duration, high disease burden, specialist prescribing, and the absence of a broad class of established oral alternatives. The main revenue exposure is currently concentrated in the branded product rather than in a large generic market.

The most attractive entry strategy is an oral product that reduces treatment friction. Radicava ORS eliminates infusion-center administration but still requires fasting and careful dosing. A product that materially improves taste, portability, resuspension, or tube administration could compete for new starts and switches even before full generic substitution.

The IV opportunity is more price-sensitive and operationally demanding. Hospitals and infusion providers can favor products with simpler handling, longer stability, reduced waste, and fewer compatibility restrictions. A sulfite-free product could gain a differentiated position, but the development program would be materially more complex than an oral excipient redesign.

What manufacturing and IP barriers affect entry?

The main manufacturing barriers are:

• Control of edaravone oxidation and degradation.
• Uniform dispersion of suspended drug.
• Consistent particle-size distribution.
• Sterile processing for the IV product.
• Container-closure integrity.
• Compatibility with oral syringes and feeding tubes.
• Microbial control during manufacture and in-use storage.
• Stability under temperature excursions.
• Reliable supply of pharmaceutical-grade surfactants and specialty polymers.

A formulation that uses common excipients may still be difficult to reproduce because process parameters can determine suspension behavior. Mixing order, shear rate, hydration time, deaeration, filling temperature, and headspace oxygen can materially affect finished-product performance.

Key Takeaways

• Radicava has separate IV and oral-suspension competitive strategies.
• Radicava ORS offers the stronger excipient opportunity because taste, suspension quality, dose delivery, and patient convenience can be differentiated.
• Sodium bisulfite is the main strategic issue in the IV product and creates a possible sulfite-free formulation opportunity.
• Citric acid, disodium phosphate, polysorbate 80, sodium hydroxide, sucralose, and water for injection define the principal excipient system in Radicava ORS.
• The most valuable IP is likely to involve formulation, manufacturing, packaging, device, and method-of-use claims rather than the edaravone molecule itself.
• ANDA entry may be possible for a sufficiently similar product; materially different formulations may require a 505(b)(2) strategy.
• Excipient licensing should focus on measurable improvements in stability, taste, dose accuracy, tube administration, or manufacturing robustness.
• Patent and Orange Book diligence must be performed at the specific claim and product level before setting a launch date or Paragraph IV strategy.

FAQs

Can Radicava ORS be reformulated with a different sweetener?

Potentially, but the alternative sweetener would need to preserve taste, chemical stability, pH, viscosity, suspension behavior, and delivered dose. A sweetener change could also affect labeling, patient acceptability, and comparative performance.

Is a sulfite-free edaravone injection commercially attractive?

It may be attractive for patients with sulfite sensitivity, but the replacement antioxidant system must maintain stability through sterilization, storage, and infusion. The regulatory and technical burden is higher than for a conventional generic copy.

Does Radicava ORS require a preservative?

The labeled inactive-ingredient list does not identify a conventional antimicrobial preservative. Microbial control therefore depends on manufacturing controls, packaging, formulation conditions, and labeled handling requirements.[2]

Can an edaravone tablet replace Radicava ORS?

Not automatically. A tablet would have to establish appropriate bioavailability, dose equivalence, safety, and labeling. It would likely require a separate regulatory strategy rather than direct substitution under an existing oral-suspension approval.

What is the best excipient investment thesis for Radicava?

A proprietary oral-suspension platform that improves taste, redispersibility, dosing accuracy, and feeding-tube compatibility offers the clearest commercial path. A sulfite-free IV platform is potentially valuable but carries greater formulation, manufacturing, and regulatory risk.

References

1. U.S. Food and Drug Administration. (2017). Radicava (edaravone) injection prescribing information. Mitsubishi Tanabe Pharma Corporation. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209176s000lbl.pdf

2. U.S. Food and Drug Administration. (2022). Radicava ORS (edaravone) oral suspension prescribing information. Mitsubishi Tanabe Pharma America, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214416s000lbl.pdf

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions on the patent certification requirements and 180-day exclusivity. https://www.fda.gov/drugs/development-resources/patent-certification-requirements-and-180-day-exclusivity/faq-patent-certification-and-180-day-exclusivity